British Journal of Cancer (2013) 108, 2643 – 2646
© 2013 Cancer Research UK All rights reserved 0007 – 0920/13
www.bjcancer.com

Keyword Index for Volume 108

^{212}Pb-TCMC-trastuzumab 2013
3′ UTR luciferase assay 2070
4EBP1 2021
5-aza-2′-deoxycytidine 579
5-fluorouracil 2505
^{90}Yttrium-PRRT 1440
9p21.3 1378

ABCG2/BCRP 2005
ABVD 49
ACCENT database 784
acetohexamide 570
acute lymphoblastic leukaemia 2334
adenoma 512, 2537
adherence 1515
adhesion 564
adjuvant therapy 1245, 1348, 1978
adolescents 2329
adrenocortical carcinoma 826, 1994
advanced gastric cancer 771
advanced oesophageal cancer 771
advanced ovarian cancer 2264
advanced solid tumours 1998
aerobic glycolysis 1624
aggressive prostate cancer 461
aging 2281
AIB1 1470
AKT 409, 1470, 2021
AKT signalling 2590
alcohol 2407
allergy 2334
allogeneic bone marrow transplantation 1092
alternative splicing 2291
AMD11070 1634
AMG 386 503
AMPK 327
anaemia 387
anal cancer 527
anastrazole 2259
androgen deprivation 9
androgen receptor 139, 1668
angiogenesis 1126, 2123, 2485
angiogenesis inhibitors 1034
angiopoietin inhibitor 503
animal model 2312
animal studies 64
anoikis resistance 121
ANPEP 420
anti-angiogenic therapy 250, 319
antibody 1449
antileukaemic 1870
anti-vascular 1306
ANXA11 rs1049550 1862
anxiety 1012
apoptosis 170, 395, 1460, 1648, 2070, 2097
ARID1B 2056
aromatase inhibitor 1408, 1515, 2259
array Comparative Genomic Hybridisation 2172
arthroplasty 1883
Asian Americans 1508
aspirin 1178, 1189
astrocytoma 587
atelocollagen 836
ATFs 881
attitudes 831, 1602
autoantibodies 107, 2045
awareness 292
axitinib 1571
Axl 621

bafilomycin 2312
Bayesian 762
β-blockers 2485
β-catenin 2130
Bcl-2 phosphorylation 1870
Bcl-xL 653, 2312
BEACOPP 49
benign breast disease 199
benign prostatic hyperplasia 1778
benign tumours 193
bevacizumab 493, 1052, 1316, 1566, 2549
BH3 mimetics 1870
biliary obstruction 1846
Bim 442
biomarkers 99, 107, 139, 342, 361, 395, 420, 644, 662, 908, 924, 932, 1052, 1100, 1298, 1316, 1712, 1822, 1846, 1854, 1925, 2448
bisphosphonates 163
bladder 1534
bladder cancer 973, 1470, 1854, 2372
body mass index 1891, 1408, 2390
bone markers 2565
bone metastasis 163, 2525, 2565
bortezomib 762
BRAF 1634, 1757, 2153
BRAF inhibitor 924
BRAF mutation 1495
brain-derived neurotrophic factor 121
brain tumour 2367
brain tumour epidemiology 715
brain tumour stem cells 2005
BRCA1 461, 1695, 1732, 2601
BRCA1 and BRCA2 genes 1579
BRCA1 immunohistochemistry 1231
BRCA1 mutation 2172
BRCA1/2 testing 1012
BRCA2 1732
BRCAness 2172
breast cancer 163, 188, 285, 549, 557, 602, 820, 848, 866, 873, 1042, 1195, 1408, 1480, 1515, 1579, 1602, 1807, 1985, 2033, 2045, 2172, 2241, 2250, 2291, 2304, 2399, 2426, 2442, 2525, 2610
breast cancer diagnosis 351
breast cancer radiotherapy 179
breast-conservative therapy 820
breast-conserving surgery 812
breath analysis 941
Breslow 1641
BTG2 973
bystander effect 91

CA125 antigen 2448
CA 19-9 1684
c-Abl 1143
cachexia 486
CA IX 402, 613
cancer at a young age 1525
cancer heritability 2419
cancer inflammation 2116
cancer management 2442
cancer pain 259
cancer registration 691, 699
cancer stem cells 1449, 2525
cancer survivors 831, 1525, 2407
capecitabine 469, 2505
carbonic anhydrase IX 429
carcinoembryonic antigen 662
carcinoid 301
carcinoid tumour 1838
carcinoma 638, 1553, 2537
carcinoma of unknown primary 39
cardiovascular risk 9
case–control 222, 240, 1899
CCID 564
CCL15 99
CD24 1449
CDA 2505
CDK6 1143
CDKN2A 1378, 2542
cediranib 493, 1316
celecoxib 2272
cell cycle 2021, 2495
cell cycle arrest 1648
cell lines 1801
cell migration 973
cell penetrating peptide 2495
cell proliferation 836
cervical cancer 1348, 1957, 2116, 2464
cervical intraepithelial neoplasia 234
cervix 908
cetuximab 771
checkpoint blockade 1560
CHEK2 461, 2601
chemokine 1634
chemoresistance 1079
chemotherapy 39, 265, 395, 486, 1027, 1071, 1425, 1684, 1771, 1931, 2005, 2063, 2264, 2250, 2485
childhood brain tumour 2346
childhood cancer 1280, 1907
childhood CNS tumours 1907
childhood leukaemia 1899, 2339
children 2334, 2346
CHIPS 587
CHK2 2601
CHOP 1340
chorionic gonadotropin 1810
circulating microRNA 932
circulating tumour cells 549, 791, 1358, 2426
cisplatin 265, 579, 859, 1245, 1695, 1994
cixutumumab 826
CK-19 549
class III β-tubulin 82
clear cell 1553
cleaved caspase-3 2097
cleaved PARP 2097
clinical benefit response 1021
clinical outcome 1042
clinical response 285
clinical trials 748, 866
clinicopathologic 1508
cluster analysis 2354
c-Met 2142
c-Myc 653
CNS development 2130
CNS PNET 2130
COBAS 2164
coffee 2381
cohort study 708, 1168, 1178, 1879, 1883, 2390
collagen genes 964
collagen receptor 163
colon 107
colon cancer 784, 791
colonic neoplasms 1425
colorectal cancer 278, 493, 662, 668, 681, 1149, 1316, 1368, 1432, 1502, 1508, 1566, 1712, 1720, 1750, 1757, 1862, 1891, 1978, 2088, 2097, 2106, 2153, 2537, 2542, 2549
colorectal neoplasm 213, 775
colospheres 1720
combination 1393
combination immunotherapy 1998
common alleles 2610
common genetic variants 1378
communication 1402
communication inequalities 1949
competing risk 1534
complement 5a 1846
comprehensive geriatric assessment 1936
consultations 686
conventional adenocarcinoma 613
COP1 2495
cost 1225, 2250
cost-effectiveness 9, 1579, 2250
COX-2 91, 1106, 2272
COX-2 inhibitor 319
Cox 784
C-reactive protein 1891
cross-sectional studies 292
CRPC 1668
cryptic 1113
CTC 2426
curriculum 1936
CXCR4 1634
CYFRA 21-1 1684
cytarabine 983
cytokeratin 1704
cytokines 1306, 1801
cytotoxic T cells 1092
cytotoxic T- lymphocyte antigen 4 (CTLA-4) 1560

D2 gastrectomy 1245
database 721
DCIS 812, 1593
decision impact 2250
decision support techniques 1810, 2448
delay 686, 1280
delivery of health care 14
dendritic cells 1092
DEPArray 1358
dephosphorylation 2590
depression 1012
desmoplasia 1
detection marker 1119
DFMO 512
diabetes 222, 1778, 727
diabetes mellitus 1182
diagnosis 25, 686, 941, 1149, 1332, 2329
diagnostic 1712, 1925
diagnostic assay 1157
diagnostic interval 1280
diagnostic marker 163, 2299
diarrhoea 1027

dichloroacetate 72, 1624
dielectrophoretic cell sorting 1358
diet 188, 205, 512, 831
diffuse-type gastric cancer 932
digital pathology 602
discrete choice experiment 533
disease-free survival 2573
disease progression 2565
Dkk2 2070
Dkk-3 1659
DNA adducts 334
DNA content analysis 873
DNA damage signalling 748
DNA methylation 131, 370, 420, 2033
DNA mismatch repair 1495, 2079
DNA repair 748
docetaxel 265, 771, 1079, 1994
docosahexaenoic acid 486
Down syndrome 2334
doxifluridine 1245
DPYS 2505
drug resistance 1810
ductal intraepithelial neoplasia 1593
dying 1942

E2F1 1470
E3 ligases 2495
E7 450
early deaths 681
early diagnosis 2045
early stage 1348
EBP1 557
E-cadherin 402
eEF1A2 2304
effect size 1790
eflornithine 512
EGFR 115, 469, 1743
EGFR family 2291
EGFR signalling 1765
EGFR-targeted therapy 668
eicosapentaenoic acid 486
elderly 311, 1534, 1936
elderly patients 519
embolisation 1252
end of life care 1273
endometrial cancer 183, 1021, 1267, 1771
endoplasmic reticulum stress (ER stress) 1340
England 775
EpCAM 881, 1480
ependymoma 2367
EPIC 708
epidemiology 179, 183, 699, 721, 1168, 1189, 1899, 1907, 2334, 2346, 2367
epidural dexamethasone 259
epidural methadone 259
epigenetic alteration 2557
epitope 1113
epothilones 82
Epstein-Barr virus 2557
Erbb4 2291
ERCC-1 115, 1238, 1695
ERK5 149
erlotinib 469
erythrocyte sedimentation rate 387
esophageal cancer 1822
estradiol 199
estrogens 199
estrone 199
EUS-FNA 1488
evaluation 1942
everolimus 1616, 1771, 2478
evidence 1225
EWOC 762
exemestane 2259
extracellular matrix 964
extranodal NK/T-cell lymphoma 380
ex vivo model 1720

FACS 2070
family history 1502
fasting blood glucose 380
fatigue 49
female 1534
fertility 1602
FISH 2582
flavonoids 1168
FLO 519
FLOT 519
fluid intake 2372
fluorescence in situ hybridisation 668
FOLFIRI 1566
FOLFOXIRI 2549
follow-up marker 1119
follow-up studies 2455
FoxO3a 442
FOXP3 155
FPR1 587
France 775

GADD34 1340
Gas-6 621
gastric adenocarcinoma 653
gastric cancer 121, 395, 941, 1245, 1324, 1495, 2557
gastric phenotype 613
gastroesophageal cancer 519
gemcitabine 469, 766, 1393, 2063
general practitioner 686
genetic polymorphism 1695, 2372
Genistein 2070
genitourinary toxicity 1964
genomic alteration 1732
genotype 676
geriatric oncology 1936
gestational trophoblastic neoplasia 1810
γH2AX 2021
glioblastoma 2005, 2142
glioma 64, 715, 1189, 2178, 2516
GLUT-1 402
glutathione S-transferase 676
glycolysis 72, 170
glycosylation 1113
GNAS 951
graft vs tumour reaction 1092
growth factors 1801
GWAS 2419

HAART and smoking 1173
haematological malignancy 2390
hazard ratio 2299
HCC 99
HDAC1 1648
HDAC 342
head and neck cancer 1178
head and neck carcinogenesis 1157
health communication 1949
health disparities 1949
health information avoidance 1949
Health-related quality of life (HRQoL) 49, 1784
height 2390
hENT1 1488
hepatitis B reactivation 1931
hepatitis B screening 1931
hepatoblastoma 334
hepatocellular carcinoma 21, 72, 222, 442, 1182, 1252, 1830
HER2 668, 873, 1807, 1985
HER4 2291
hereditary 1732
hereditary cancer 1579
herpes zoster 721
HES 1273
heterogeneity 479
H-HPV 613
HIF 1133
Hif-1α 429
high-voltage overhead power lines 1899
HIPEC 1432
hip prosthesis 1883
histone deacetylase inhibitors 748
histopathology 866
HNSCC 1648
Hodgkin lymphoma 49, 1163, 2399
hospital admissions 1273
HPV 908, 1332
HPV16 229, 240, 450
HPV16 + cervical cancer 859
HPV16 + E6 oncogene 859
HPV16 + HNSCC 859
HPV infection 1157
HPV integration 229
H.pylori gastritis 1113
hTERT 278, 2272
human fecal microbiome 1163
human-in-mice model 2525
human papillomavirus 240
hyaluronic acid 1
hyaluronidase 1
hygiene hypothesis 1163
hypermethylation 1368
hypoxia 1133

ibuprofen 1178
ICAM-1 564
IDH1-R132H 2142
IGF-1 199
IGF-1R pathway 826
image analysis 602
imaging 662
immune microenvironment 914
immune/inflammatory cell infiltration 914
immunisation 1092
immunohistochemistry 602, 924, 1267, 1830, 2164, 2582
immunotherapy 1288, 1560, 2281
incidence 1899, 2367, 2381
individually tailored breast cancer screening 2241
infections 2478
infectious disease 2346
inflammation 997
information provision 1602
information technology 2433
ING1 1143
inguinal lymph node 527
inherited susceptibility 2178
integration 629
integrin 1460, 2516
interaction 1173, 1778
intercellular adhesion molecule 2 (ICAM2) 1817
interleukin-1β 2063
interleukin-6 1891, 2063
interstitial fluid pressure 1
intracranial xenografts 64
intraperitoneal chemotherapy 1231
intra-tumour 479
intrauterine devices 234
intrinsic subtypes 1480
intronic deletion 438
invasion 99, 2516
invasion assay 2070
invasive breast cancer 542
ipsilateral recurrence 812
iron chelators 409
isoxsuprine 570
ITIH3 1846

Japanese survey 629

Kaplan–Meier 784
Kaposi's sarcoma risk 1173
Ki-67 271, 1593
Ki-67 antigen 1838
kinase inhibitor 334
KRAS 115, 951, 1757, 2153
KRAS mutation 1495

late effects 1525
lead time 1971
lenalidomide 1801
letrozole 1587, 2259
leukaemia 2390
leukocytes 1306
life expectancy 1971
lifestyle factors 1508
LIFR rs3729740 1862
liquid biopsy 2426
Listeria monocytogenes 2281
liver 676
liver cirrhosis 21
liver function 21
liver metastases 1566, 2549
Liverpool Care Pathway 1942
liver toxicity 2549
LKB1 327
lncRNA 2419
lobular carcinoma 285
lobular endocervical glandular hyperplasia 613
localised prostate cancer 271, 2464, 2582
log-normal 784
longitudinal 2407
long-term effects 179
long-term medical consequences 1525
low-dose tamoxifen 1593
low-grade mucinous appendiceal neoplasm 951
LRIG1 1765
lung 91
lung cancer 629, 1288, 1879
lymphatic endothelium 564
lymphendothelial intravasation 570
lymph node 2106
lymph-node metastasis 1267
lymphoma 2390
Lynch syndrome 2079

macrometastasis 1267
macrophage inhibitory cytokine-1 1079
maintenance therapy 2264
male breast cancer 959, 2259
male infertility 1004
malignant mesothelioma 621, 1743
malignant neoplasm 193
malignant outcome 1324
malignant peripheral nerve sheath tumour 964
malignant potential 2033
mammalian target of rapamycin inhibitor 1021
mammographic calcifications 812
MAPK 1460
margins 285
mass spectrometry 351
matricellular proteins 755

© 2013 Cancer Research UK

matrix metalloproteinase 1149
MCF7 cells 2304
medical record linkage 1883
melanoma 924, 1560, 1634, 1641, 1998, 2164
melatonin 442, 2005
men 533
Merkel cell polyomavirus 629
mesothelioma 1340
MET 1100
meta-analysis 39, 64, 798, 2299, 2478
metabolic syndrome 222
metabolism 327
metalloproteinases 964
metastasectomy 1425
metastasis 265, 493, 549, 1079, 1432, 1541, 1634, 1668, 1704, 2106, 2470
metastatic breast cancer 1052, 2281
metastatic colorectal carcinoma 503
metastatic solid tumours 1061
methotrexate 1810
methylation 1750, 2542
MET inhibitor 21
metronomic chemotherapy 250
mFOLFOX6 493
mFOLFOX 791
MHC-II 2097
microarray 107, 370
micrometastasis 1267, 2426
microRNA 131, 361, 1817, 1822, 1925
microRNA-18a 653
microRNA profile 1712
microsatellite instability 1750, 1757, 2079
microtubules 82
midkine 1854
migration 99, 587
minimal deviation 613
mir-124-3 131
miR-1246 644
miR-125b 1817
miR-1260b 2070
mir-143 149
miR-145 2573
mir-203 1143
miR-205 1668
miR-29c 964
miR-663 2304
miR-744 2304
miR-874 1648
miRNA 1133, 1668
miRNA-183 1659
mismatch repair 983
mitochondria 2485
mitochondrial peptides 587
mitomycin-C 1245
mitotic count 1838
mitotic spindle checkpoint 2013
MLH1 983
MMR status 1238
molecular 1553
molecular characterisation 1157, 2426
molecular tumour markers 2573
morbidity 32
mortality 179, 188, 1515, 1534, 1757
mortality trends 2354
MSH2 983
MTHFR 2505
mTOR 429, 1616, 2021
mTOR inhibition 1771, 2478
mTOR pathway 826
MTS assay 2070
MUC1 1113
MUC1 aberrant glycoforms 2045
mucinous adenocarcinoma 1978
mucinous histology 1978
multicentre study 1495
multidisciplinary case conference 2433
multidisciplinary teams 2442, 2433
multiparametric flow cytometry 873
multiple myeloma 170, 1624, 1801
multi-state Markov model 542
multi-state multi-variable model 2241
mutation 629, 1368
mutation analysis 1743
Myeloid-derived suppressor cells 2281
myofibroblasts 2106

NBN 461, 2601
NBS1 461, 2601
NDRG1 409
needle biopsy 271
negative regulators 597
neoadjuvant chemotherapy 285, 519, 866, 1566, 1587, 1807, 1957, 2172, 2464
neoplasm 14, 292, 1810, 1883, 2381, 2537
neratinib 1985
nestin 2142
neuroblastoma 2485
neuroendocrine 301
neuroendocrine tumour 1298, 1440, 1838
neurofibromatosis 193
neurofibromatosis type 1 964
neutrophil/lymphocyte ratio 1677
next-generation sequencing 479
NGAL 2537
NGR–hTNF 58
nifedipin 570
nitrate 205
nitrite 205
non-aspirin NSAIDs 1189
non-small-cell lung carcinoma 1415
non-targeted response 1106
Norway 1525
Notch3 1488
NSCLC 265, 1695

obesity 222, 727, 1408
oesophageal squamous cell carcinoma 644
oesophago-gastric cancer 25
oestrogen receptor 155
oestrogen sulphotransferase 1415
off-target effects 450
older women 1042
oncologists 1602
oncologists' views 2264
oncology 1071, 1273
oncolytic 245
one-carbon metabolism 183
oral contraceptives 234
oral squamous cell carcinoma (OSCC) 370, 1817
oral tongue cancer 638
oropharyngeal 1332
osteosarcoma (OS) 836
osteotropism 2525
outcome 887
ovarian cancer 250, 881, 1231, 1553, 1732, 2039, 2448
ovarian cancer relapse 32
ovarian neoplasm 2448
overall survival 32, 2565
overdiagnosis 1971
oxaliplatin 115, 265, 676, 1238, 1978
oxidative phosphorylation 72
oxidative stress 848

p16 immunohistochemistry 1157
p16^{INK4A} 229
p28 1061
p53 107, 1061, 2495, 2573
p53 mutant 873
paclitaxel 1985, 2013
PAK1 557
palliative care 1273
pancreatic cancer 361, 469, 766, 914, 997, 1684, 1846, 2056, 2063
pancreatic ductal adenocarcinoma 1
pancreatic neoplasms 1168
paraganglioma 429
parent-of-origin effects 2610
parity 234
paternal occupation 1907
pathological complete response 285, 1587
pathologic response 2549
patient care planning 14
patient reported outcomes 301, 1571
patients' views 2264
PDK1 170
penetrance 2610
penile cancer 229
peptide vaccine 1260
perceived probability of genetic predisposition to cancer 1012
period analysis 699
periodate 1113
peritoneal carcinomatosis 1432
persistent human papillomavirus infection 234
personalised cancer treatment 1358
PET 342
PF-3512676 1998
Phaeochromocytoma 429
pharmacodynamic 58, 1298
pharmacokinetics 1393
pharmacology 342, 1071
phase I trial 762, 826, 1260
phase II 1994
phase III trial 1957
phosphorylation 139, 2590
physical activity 798, 831, 2407
PIAS3 653
PIGR 1846
PIK3CA 1807
pineoblastoma 2130
plasma 361, 1822
plasma marker 163
platinum 2039
podocalyxin-like protein 2321
polyamines 512
polymorphism 438, 1126
polyunsaturated fatty acids 486
pooled analysis 727
population-based 1195
population-based data 691
population-based study 775
population studies 2455
positive predictive values 25
post-bereavement survey 1942
postoperative relapse 791
potential drug–drug interactions 1071
PP2A subunits 2590
predictive 1052, 1925
predictive biomarker 1238
pregnenolone sulphate 1415
premalignant 2033
primary care 25, 1280, 2329
proadifen 570
progesterone receptor 1415
prognosis 131, 155, 370, 380, 395, 420, 621, 901, 914, 1100, 1119, 1133, 1332, 1593, 1810, 1830, 1838, 1925, 2153, 2321, 2542
prognostic biomarker 387, 1677
prognostic factors 271, 681, 1324, 1480, 2088, 2312, 2470, 2582
prognostic marker 278, 2299
programmed death-1 (PD-1) 1560
proliferation 1470
promoter methylation 2005
pro-opiomelanocortin 1704
prophylactic antiviral therapy 1931
prospective study 213, 2381
prostate cancer 9, 139, 149, 409, 420, 597, 708, 1079, 1225, 1659, 1668, 1778, 1784, 1879, 1925, 1964, 1971, 2123, 2381, 2565, 2573, 2590, 2601
prostate cancer screening 533
prostatectomy 1784
prostatic neoplasm 2354
prostatitis 1778
protein phosphatase type 2A 2590
proteomics 351
proton beam 1225
proxy 1942
PSA 533, 2601
psychology 1004
PTEN 409, 438, 2582
publication bias 64
pyrosequencing 2164

Quadruple index 2153
quality of care 1942
quality of life 301, 1225, 1571, 1790
quaternary cytoreduction 32

radiation 91, 1106, 1225
radiation-induced neoplasm 1579
radiation-related heart disease 179
radiation-related lung cancer 179
radiation therapy 1964
radical hysterectomy 1348
radical surgery 1957
radioimmunotherapy 859
radioresistance 1817
radiotherapy 812, 1593, 1784
RAF inhibitors 1298
Raf kinase inhibitor protein 2088
randomised 1402
randomised trial 812
rates 2455
RCC 2070
real-time RT-PCR 2070
RECIST 1252
record linkage 193
rectum 107
recurrence 188, 1119, 1515
referral 686, 1149
REG 395
registration errors 691
regression 1790
regulatory RNA 2419
relative survival 691
renal cancer 205, 798, 1133, 1616
renal cell carcinoma 131, 205, 311, 319, 327, 387, 887, 901, 1034, 1126, 1260, 1541, 1571, 2470, 2478
resection 1425
resistance 2039
response 1440
resveratrol 2304
retinoblastoma 2455
retrospective likelihood 2610
ridaforolimus 1021
risk 721, 1149, 1189, 1883, 2178
risk factors 213, 542, 727, 1071, 1432

© 2013 Cancer Research UK

risk of cancer 193
risk stratification 2573
RKIP 2088
RNAi 245

S1 1870
sagopilone 82
Sanger 2164
sarcomas 2455
sarcopenia 1034
SCC 1332
screening 245, 1579, 1971, 1508, 2045, 2601
second tumours 2455
secretome 1854
segregation analysis 2610
semen cryopreservation 1004
sensitivity 542
sensitivity and specificity 2299
sensor 941
sentinel lymph node 527, 1267
serum 1149, 1712
serum microRNA 644
sex chromosome aneuploidy 959
sexual behaviour 234
sexual function 49
sFRP1 2070
side effects 1784
signal transduction 1298
simulation 691
simulation model 1579
single-cell analysis 1358
single-nucleotide polymorphisms 887
sinusoidal obstruction syndrome 676
siRNA 450
skeletal-related events 2565
sleep 213
SMAD2 409
SMAD4 1659
Smad4 2070
smoking 708, 2407
SNPs 2601
social contact 2346
social security benefits 1525
socioeconomic status 1907, 2339
soft-tissue sarcoma 1677
sojourn time 542
solid tumours 1393, 1931
soluble tumour necrosis factor receptor 2 1891
somatostatin receptor 1 2557
sorafenib 72, 311, 334, 1571
Sox11 2142
spheroid 579
spinophilin 1830
splice-switching oligonucleotide (SSO) 2291
SPRED1 597
SPRED2 597
squamous cancer 527
squamous cell carcinoma 638
Src 1143
SRC3 2039
stable disease 1021
stage III colon cancer 1238
staging 527, 1195
STAT3 653
statins 715
stem cell 1765
stem-like cell 2516
stereology 2116
steroid sulphatase 1415
stress reactions 1012
stromal resistance 1
study population 699
sulindac 512
sunitinib 319, 762, 887, 1034, 1126, 1393, 1541, 2470
supportive care 2264
supradiaphragmatic radiotherapy 2399
surgical–pathological risk factor 1348
surgical treatment 1119, 1566
survival 387, 461, 681, 775, 784, 1195, 1440, 1502, 1508, 1541, 1641, 1757, 2164, 2339, 2367, 2470
survival analysis 699
survival rate 292
survivin 653, 848
survivors 14
survivorship 1163
Sweden 1541
SWI SNF 2056
Sylamer 450
symptom control 1027
symptoms 25
synthetic lethality 983
systematic review 39, 2299
systems pathology 602

TACE 1252
TAE 1252
tamoxifen 557, 1408, 1515
targeted chemotherapy 1862
targeted immune modulator 1998
targeted therapy 311, 924, 1079, 1553, 1616, 1743
taxotere 1994
teachable moment 2407
teenagers 2329
telemedicine 2433
telomerase 1368, 2272
temozolomide 64
temsirolimus 2478
testosterone 199
TGF-β 1106
TGFBR 1106
therapeutics 479
therapy 997, 1553
therapy response 2088
three-dimension 1720
timing radiotherapy 820
tissue biomarkers 351
tissue microarray (TMA) 420, 1340
tivantinib 21
TLR9 1616
Toll-like receptor 5 638
TOPflash 2070
toxicity 1560, 1784
training 1936
transcriptional regulation 1143
transforming growth factor-β 91
translational research 2241
trastuzumab 1807
treatment outcomes 1034
trebananib 503
Treg 155
tremelimumab 1998
trial participation 1402
trichostatin A 579
triple-negative breast cancer 1100, 2172
tropomyosin-related kinase B 121
TUBB3 82
tumorigenicity 579
tumour 342
tumour-associated macrophages 1288, 2116
tumour-associated neutrophils 2116
tumour-associated stroma 2097
tumour board 2433
tumour cell invasion 755
tumour dissemination 32
tumour grading 1838
tumour growth 334
tumour hypoxia 402
tumour immunity breast cancer 155
tumour immunology 1288
tumour invasiveness 402
tumour microenvironment 755, 1677
tumour spheroid 570
tumour spheroid intravasation 564
tumour suppressor 973, 1765
tumour suppressor gene 1368, 2056, 2557
twin study 1163
TYMS 2505
tyrosine kinase inhibitors 250, 311, 1541, 1985
TYRP1 1641

ubiquitination 2495
UDP-glucuronosyltransferase 2372
ulceration 1641
ultrasonography 2448
underground mining 1879
unresectable pancreatic cancer 1488
uPA inhibitor 766
upper urinary tract 2312
urine 1854
urothelial 1534
urothelial carcinoma 1368, 2312, 2321
uterine cervix cancers 402
uterine sarcoma 727

V600E 924
vaccine therapy 1260
validation study 901
Van-Gogh-like 2 1750
vascular disruptive agents 250
vascular endothelial growth factor 1052
vascular endothelial growth factor receptor 1260
vascular targeting agent 58
vasohibin-1 2123
VEGF 429, 1052, 1126, 1316, 1460
VEGF-A 1034
VEGF inhibitors 250
VHL 1133
vincristine 2485
viral hepatitis 1182
viral load 229
virotherapy 245
virtual teams 2433
volatile organic compound 941

weight loss 831
western blot 2070
WNT 1750
WNT pathway 2130
women 213
worldwide 240

xanthenones 1306
xenografts 334, 848, 1306, 1704

Y-box binding protein-1 (YB-1) 836
younger adult 1602
YWHAZ (14-3-3ζ) 1324

zinc-fingers 881

© 2013 Cancer Research UK